Fig. 6: Biomarker subgroup analysis of tpCR rates in the ITT population. | Nature Communications

Fig. 6: Biomarker subgroup analysis of tpCR rates in the ITT population.

From: Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial

Fig. 6: Biomarker subgroup analysis of tpCR rates in the ITT population.

Boxes represent sample sizes and odds ratios; whiskers represent 95% CI; the vertical dotted line represents the odds ratio for all patients. CI confidence interval, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, ITT intention-to-treat; mRNA, messenger RNA, PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, PTEN phosphatase and tensin homolog, tpCR total pathologic complete response.

Back to article page